Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.’s position as a global leader in biopharmaceutical innovation.

As part of the deal, Pfizer has voluntarily committed to aligning U.S. drug prices with those in other developed countries. Newly launched medicines will also be priced at parity with key international markets. In addition, Pfizer will participate in the TrumpRx.gov platform, allowing U.S. patients to purchase many of the company’s medications—particularly in primary care and select specialty areas—at discounts averaging 50%, with some as high as 85%.

While specific terms of the agreement remain confidential, Pfizer emphasized that the deal offers benefits on multiple fronts. “This is a win for American patients, a win for American leadership, and a win for Pfizer,” said Albert Bourla, Pfizer Chairman and CEO. He added that the agreement ends the long-standing burden on U.S. patients who often pay higher prices than those in other countries and provides stability for the company to invest further in domestic innovation.

The agreement includes a three-year tariff grace period for Pfizer products under Section 232 investigation, contingent on the company boosting U.S.-based manufacturing. This provision ensures Pfizer will not face tariffs during that period while further incentivizing domestic investment.

Pfizer also announced plans to invest an additional $70 billion into U.S. research, development, and capital projects in the coming years. This builds on the more than $83 billion the company has already committed to American biotech innovation from 2018 to 2024. Pfizer’s U.S. workforce of 31,000 spans 13 manufacturing and distribution facilities and seven major research and development centers.

With this agreement in place, the company says it can now focus fully on advancing its core scientific priorities, including breakthroughs in oncology, obesity, vaccines, and immunology.